Why is Krebs Biochem falling/rising?

As of 26-Sep, Krebs Biochemicals & Industries Ltd is experiencing a decline in its stock price, currently at Rs 70.50, reflecting a decrease of 3.64 points or 4.91%. The stock has underperformed its sector by 2.57% today and has been on a downward trend for the last three days, accumulating a total loss of 12.96% during this period. Key financial indicators reveal that the company has reported negative results for the last three consecutive quarters, with net sales and profit after tax both declining by 53.42%. Additionally, the company has a negative book value and a weak long-term fundamental strength, as evidenced by a debt-to-equity ratio of zero and poor growth rates in net sales and operating profit over the past five years.
In the broader market context, Krebs Biochem's performance has been notably weaker than the benchmark, with a year-to-date return of -23.78% compared to the Sensex's gain of 2.93%. The stock has consistently underperformed against the benchmark over the last three years, further contributing to investor skepticism. The pharmaceuticals and drugs sector has also seen a decline of 2.35%, which may be impacting investor sentiment towards Krebs Biochem. With falling investor participation and liquidity issues, the stock's current trajectory appears to be influenced by both company-specific challenges and broader market conditions.